Haleon plc (LON:HLN - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 419.21 ($5.66) and last traded at GBX 415.10 ($5.60), with a volume of 455263938 shares trading hands. The stock had previously closed at GBX 411.60 ($5.56).
Analyst Ratings Changes
Separately, Berenberg Bank increased their target price on Haleon from GBX 456 ($6.15) to GBX 457 ($6.17) and gave the company a "buy" rating in a report on Friday, February 28th.
View Our Latest Analysis on Haleon
Haleon Stock Performance
The business has a fifty day simple moving average of GBX 389.11 and a 200 day simple moving average of GBX 383.64. The stock has a market cap of £37.47 billion, a price-to-earnings ratio of 34.92, a PEG ratio of 1.49 and a beta of 0.19. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84.
Haleon (LON:HLN - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.21) EPS for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, equities analysts anticipate that Haleon plc will post 19.5033282 EPS for the current year.
Insiders Place Their Bets
In other Haleon news, insider Asmita Dubey purchased 15,424 shares of Haleon stock in a transaction on Friday, May 2nd. The shares were bought at an average price of GBX 401 ($5.41) per share, with a total value of £61,850.24 ($83,479.88). Also, insider Marie-Anne Aymerich acquired 21,300 shares of the business's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of GBX 405 ($5.47) per share, for a total transaction of £86,265 ($116,432.72). Insiders have acquired a total of 42,869 shares of company stock valued at $17,294,104 in the last quarter. 10.74% of the stock is currently owned by company insiders.
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.
See Also
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
